Navigation Links
£3m drug safety center investment

LIVERPOOL, UK 29 January 2014: The Medical Research Council (MRC) Centre for Drug Safety Science at the University of Liverpool has received three million pounds of new funding from MRC to allow it to continue reducing the impact of adverse reactions to medicinal drugs.

Adverse drug reactions result in one in 15 hospital admissions and cost the NHS in excess of 650 million every year. They are also a significant cause of drug attrition for the pharmaceutical industry. The Centre addresses these problems by gaining an understanding of the fundamental mechanisms that drive adverse drug reactions to improve patient care.

The new funding will allow the Centre to consolidate its main areas of research on drug-induced liver injury and drug-induced skin hypersensitivity, for which it is internationally renowned. The funding will also enable the development of new expertise in the significant clinical problem of gastrointestinal drug toxicity.

Training is a significant part of the Centre's mission and the funding will allow it to continue to train the next generation of clinical and non-clinical drug safety scientists to bridge the skills gap in this area for pharmaceutical companies, the biotechnology sector, contract research organisations and academia.

The Centre works alongside partners from academia, regulatory authorities and industry and has attracted over 16 million in additional funding since it was set up in 2008.

Professor Kevin Park, Director of the Centre said: "This is good news for the University of Liverpool and highlights the value that the MRC sees in our national centre of excellence. It is also good news for the people who are affected by adverse reactions to medicines".

Professor Munir Pirmohamed, Head of Department of Pharmacology said: "This highlights the critical mass of expertise we have in drug safety in Liverpool. The new funding and new equipment will allow us to continue to train scientists and clinicians and translate our research into both medical practice and drug development processes. Ultimately we want to make drugs much safer for everybody."

Dr Nathan Richardson, Head of Molecular and Cellular Medicine, MRC said: "The Centre has built up an impressive bio-analytical and training facility in the first five years of core funding, with partnerships between academics, clinicians, industry and regulatory authorities.

"Positioned as a key part of MRC's portfolio in drug safety science research, we are delighted to continue strategic support for the Centre, and look forward to seeing increasing impact of its research in clinical care, including through the new research area of gastrointestinal toxicity."


Contact: Jamie Brown
University of Liverpool

Related biology news :

1. Scientists awarded £3M to study the way Northwest European seas absorb carbon
2. Aspartame passes stiff review by European Food Safety Authority
3. Safety in numbers? Not so for corals
4. Duke wins $15 million renewal to study nanotech safety
5. UH among Texas institutions that will lead Ocean Energy Safety Institute
6. Findings announced from landmark study on safety of adolescent bariatric surgery
7. Reassuring findings released in national study of influenza vaccine safety in pregnancy
8. Seafood still considered a good source of nutrients but consumers confused on safety
9. RNA-interference pesticides will need special safety testing
10. Revolutionary Face Recognition Media Exploitation System Now Available to Enhance Public Safety in Europe
11. Additional research must be done to ensure safety of pit latrines, new study says
Post Your Comments:
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court ... issued another key ruling in favor of Crossmatch ... Korean fingerprint scanner company Suprema and its U.S. partner ... 1930, a trade provision that declares it unlawful to ... by infringing two of Crossmatch,s patents, the 5,900,993 patent ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced that Lenovo has selected Synaptics , ... FS4202, for its latest smartphone, the Vibe P1. The ... to unlock the device and provide swift access to ... The feature-rich Natural ID FS4202 sensor solution utilizes AES256-bit ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... Mass. , Oct. 13, 2015 Applied ... methodologies at critical decision points throughout the drug invention ... QSP Congress Boston 2015 on October 20-22, 2015 in ... Burke , PhD, Co-Founder, President, and CEO of Applied ... discovery from early research to clinical trials" on Wednesday ...
(Date:10/13/2015)... PARK, N.J. and SAN DIEGO ... (BASF) and Mast Therapeutics, Inc. have agreed to collaborate ...  Currently, excipient-grade poloxamer 188 NF, marketed by BASF under ... used in a variety of pharmaceutical and biological applications, ... Poloxamer 188 is the starting material for Mast,s lead ...
(Date:10/13/2015)... and TORONTO , Oct. 13, 2015 /PRNewswire/ ... that it has entered into a non-binding Letter of Intent ... Israeli company that has developed a proprietary cooling technology designed ... varicoceles. the United States and ... the ages of 25 and 44 diagnosed as infertile.  For ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... is excited to announce their partnership with the Keck Medicine of the ... chronic pain. , The T.R.O.J.A.N. Study (Therapeutic Evaluation to Research Clinical Objectives Linking ...
Breaking Biology Technology: